Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7921819 | 0.89 | ALDH1A1 (0.53) | MAPTGABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL24074581 | 0.86 | ALDH1A1 (0.58) | ALOX15MAPTGABRA1GABRB1GABRA3 | |
| SCHEMBL8795754 | 0.85 | ALOX15 (0.61) | ALOX15MAPT | |
| SCHEMBL24113129 | 0.85 | MAPT (0.48) | ALOX15MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL28477589 | 0.84 | KDM4E (0.64) | ALOX15MAPTGABRA1GABRB1GABRA3 | |
| SCHEMBL30071216 | 0.82 | ALOX15 (0.54) | ALOX15MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL20494685 | 0.82 | ALOX15 (0.54) | ALOX15MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL28640836 | 0.82 | ALOX15 (0.73) | ALOX15MAPTGABRA1GABRB1GABRA3 | |
| SCHEMBL29955347 | 0.82 | ALOX15 (0.73) | ALOX15MAPTGABRA1GABRB1GABRA3 | |
| SCHEMBL21822255 | 0.81 | ALOX15 (0.47) | ALOX15MAPTKDM4EALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243202-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-31 | — | — | US | disclosed |
| CN-115785100-B | Compounds useful as RET inhibitors | 癌症研究科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240132504-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| US-11680068-B2 | Compounds useful as RET inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| CN-115785100-A | Compounds useful as RET inhibitors | 癌症研究科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-4105219-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS RET INHIBITORS | Cancer Research Technology Limited (GB) | 2022-12-21 | — | — | EP | disclosed |
| US-20220348585-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-11-03 | — | — | US | disclosed |
| CN-110506043-B | Compounds useful as RET inhibitors | 癌症研究科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-11352361-B2 | Compounds useful as RET inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| EP-3609898-B1 | COMPOUNDS USEFUL AS RET INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-06-01 | — | — | EP | disclosed |
| US-20200157107-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-21 | — | — | US | disclosed |
| EP-3609898-A1 | COMPOUNDS USEFUL AS RET INHIBITORS | Cancer Research Technology Limited (GB) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018189553-A1 | COMPOUNDS USEFUL AS RET INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243202-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | ALOX15 3511/4885MAPT 3607/4885GABRA1 2548/4885 |
| US-20220348585-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | ALOX15 3511/4885MAPT 3607/4885GABRA1 2548/4885 |
| US-11352361-B2 | Compounds useful as RET inhibitors | RET, BCR, REL | ALOX15 3511/4885MAPT 3607/4885GABRA1 2548/4885 |
| US-20200157107-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | ALOX15 3511/4885MAPT 3607/4885GABRA1 2548/4885 |
| US-20240132504-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | ALOX15 3511/4885MAPT 3607/4885GABRA1 2548/4885 |
| US-11680068-B2 | Compounds useful as RET inhibitors | RET, BCR, REL | ALOX15 3511/4885MAPT 3607/4885GABRA1 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.